FDA
-
-
-
-
-
-
-
ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
-
-
-
-
-
-
-
ESSA Pharma Announces Proposed Public Offering of Common Shares
-
-
-
-
-
-
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
-
-
-
-
-
-
-
ESSA Pharma Board of Directors Approves Stock Option Plan, RSU Plan and Option Grants
-
-
-
-
-
-
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2018
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

